X

Trial Profile

A phase III study comparing nivolumab with nivolumab plus docetaxel in patients with previously treated advanced non-small-cell lung cancer: a randomized phase II/III trial(TORG1630)

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 31 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Docetaxel
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms CONDUCT study; TORG1630

Most Recent Events

18 Aug 2022 Status changed from active, no longer recruiting to completed according to results published in the Clinical Cancer Research.
18 Aug 2022 Results published in the Clinical Cancer Research
07 Jun 2022 Primary endpoint (Phase III: Overall survival) has been met, according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com